Focus

Cell Therapy Investors: Angels and VC Firms

The RaiseHunt database lists 146 Cell Therapy investors: 11 angel investors and 135 people at 42 firms. Most list Seed and Series B among their stages; the largest hubs are San Francisco, New York and London.

Strongest in San Francisco, New York and London

Common stages: Seed and Series B

146
Cell Therapy investors
11
Angel investors
135
People at VC/PE firms
42
Firms tagged

Skip the browsing. Let AI find your ideal investors in one minute.

Paste your startup website and AI picks your best-fit investors out of 135,000+ profiles.

146 Cell Therapy investors

Showing 1-20

Filters
Larry Lasky
Larry Lasky

Investor

Sausalito, United States
Venture capital
Healthcare
View profile
Tim Bliss
Tim Bliss

Investor Relations & Finance

United States
Corporate VC
Healthcare
View profile
Minglin Ma
Minglin Ma

Executive Director

Ithaca, United States
Corporate VCFamily Office
AIClimate
View profile
Jeff Goater
Jeff Goater

Partner

Boston, United States
Venture capital
Healthcare
View profile
Anthony Arceci
Anthony Arceci

Biotech Investor

Boston, United States
Venture capital
Healthcare
View profile
Carla Daniel
Carla Daniel

Partner & Chief People Officer

San Francisco, United States
Venture capital
Healthcare
View profile
Kush Parmar
Kush Parmar

Managing Partner

Boston, United States
Venture capital
Healthcare
View profile
Max Farina
Max Farina

Principal

San Francisco, United States
Venture capital
Healthcare
View profile
John Prufeta
John Prufeta

Founder & General Partner

New York City, United States
Venture capital
Healthcare
View profile
Leon Chen
Leon Chen

Partner

Palo Alto, United States
Venture capital
Healthcare
View profile
Sarah Hymowitz
Sarah Hymowitz

Partner

San Francisco, United States
Venture capital
Healthcare
View profile
Joni Mancini
Joni Mancini

Managing Partner

Manhasset, United States
Venture capital
Healthcare
View profile
Bill Fisher
Bill Fisher

Senior Consultant

Chattanooga, United States
Corporate VC
Healthcare
View profile
Brian Halak
Brian Halak

Managing Partner

Wayne, United States
Corporate VCVenture capital
AIHealthcare
View profile
John Josey
John Josey

Partner

Dallas, United States
Venture capital
Healthcare
View profile
Kim Kamdar
Kim Kamdar

Managing Partner

San Diego, United States
Venture capital
Healthcare
View profile
Michael Rape
Michael Rape

Investigator

San Francisco, United States
Family OfficeVenture capital
EducationHardware
View profile
Zeev Zehavi
Zeev Zehavi

Vice President

Petah Tikva, Israel
Corporate VC
Healthcare
View profile
Donghong wu
Donghong wu

Investor

Beijing, China
Family OfficePrivate equity
Healthcare
View profile
John wu
John wu

Investor

Beijing, China
Family OfficePrivate equity
Healthcare
View profile

106 of 146 Cell Therapy investors, A to Z

Grouped by first letter. Name and profile link only, the detailed rows are in the table above.
Show

A10

  • Abraham Bassan
  • Aditya Asokan
  • Alan Barge
  • Alexander Munoz
  • Alexis Ji
  • Amit Shah
  • Andrew Bartynski
  • Andy Schwab
  • Arie Belldegrun
  • Arturo Urrios

B3

  • Birthe R.
  • Brian Daniels
  • Brian Kickham

C1

  • Chong Yoon Rha

D4

  • David Goeddel
  • David Goeddel
  • David Parry
  • Deborah Palestrant

E3

  • Egen Atkinson
  • Eric Heil
  • Erika Lakos

F1

  • Florian Alexander Bettin

G4

  • George Seabridge
  • Gregory A Bonfiglio
  • Guillem Laporta
  • Gunaretnam Rajagopal

H4

  • Hao Wu
  • Heath Lukatch
  • Hiroko Kimura
  • Hui Tian

I1

  • Iñigo López-Huerta Anitua

J19

  • Jake Nunn
  • Jake Rhyner
  • Jalal Taleb
  • Jeremy Caldwell
  • Jesse Dong
  • Jian Wang
  • Jiazhen Chen
  • Jill Carroll
  • Joël Jean-Mairet
  • John Diekman
  • John Diekman
  • Jonathan Hay
  • Jordi Xiol
  • Joseph Victor
  • Joshua Kennedy-Smith
  • Julia Salaverria
  • Jung Hyun Kim
  • Justin Xiang
  • Juyeol Choe

K4

  • Karen Wagner
  • Karimah Es Sabar
  • Katie Bodner Spielberg
  • Koji Yasuda

L4

  • Lauren Cujé
  • Lisa Schechner
  • Logan Brock
  • Long Tang

M10

  • Marcos Milla
  • Marietta Wu
  • Martin Blüggel
  • Michael Diem
  • Michael Kramarz
  • Mike Dybbs
  • Mike Rice
  • Milesh Patel
  • Millie Ray
  • Mitchell Mutz

N4

  • Nate Tower
  • Nathan Fischel
  • Naveen Yalamanchi
  • Niklas Prager

O1

  • Olav Carlsen

P8

  • Patricia Ledecky
  • Patrick Doyle
  • Paul Lu
  • Perry Nisen
  • Peter Fong
  • Peter Svennilson
  • Philip Habib
  • Piratip Pratumsuwan

Q1

  • Qinda Ye

R9

  • Rajeev Dadoo
  • Rathnam Venkat
  • Raúl Martín-Ruiz
  • Rick Klausner
  • Robert Baffi
  • Roderick Wong
  • Roger Kang
  • Rosie Barnett
  • Ruize

S9

  • Scott Rocklage
  • Seamus Mulligan
  • Shun Asami
  • Shunsuke Nakaji
  • Srini Akkaraju
  • Stella Xu
  • Stephanie A. Sirota
  • Stephen Shuttleworth
  • Steve Schmidt

T3

  • Tim Kutzkey
  • Ting Guo
  • Tracy Ooi

Y1

  • Yingying Yang

Z2

  • Zafrira Avnur
  • Zhanghang Yan

Frequently asked questions

How many Cell Therapy investors are on RaiseHunt?

RaiseHunt currently lists 146 Cell Therapy investors.

Are Cell Therapy investors angels or funds?

Both. 11 are angel investors putting in their own money, and 135 are people making investment decisions at 42 firms.

Where are most Cell Therapy investors based?

The largest concentrations are in San Francisco, New York and London.

What stage do Cell Therapy investors invest at?

Most list Seed and Series B among the rounds they take part in.

How do I contact Cell Therapy investors?

Every profile shows whether an email address is on file. The addresses themselves, along with AI matching and outreach, are in the RaiseHunt app.

Is the list of Cell Therapy investors free to browse?

Yes. The directory and every profile page are free to read. Matching your own startup against them requires an account.

Do Cell Therapy investors only back Cell Therapy companies?

No. A focus area is a signal of interest, not a restriction. Investors usually list several, and the useful question is whether their existing portfolio looks like the kind of company you are building.

What do investors look at first?

The team and the problem, in that order, before the product. Early on there is rarely enough traction to argue from numbers alone, so the question they are answering is whether these particular people are likely to work this problem out.

Should I raise from one investor or several?

Several, in almost every case. A single backer concentrates the risk of the round collapsing if that one conversation goes cold, and a group brings more introductions later. Rounds are usually assembled from a lead plus others who follow.

How do I follow up without being annoying?

Follow up with new information rather than a reminder. A short note saying what changed since you last wrote gives the reader a reason to reply, where "just checking in" gives them none. Two or three of those, spaced out, is normal and expected.

What if no Cell Therapy investor replies?

Usually the list was too short or too loosely matched, not that the company is unfundable. Widen it, tighten who you are writing to, and rewrite the first two lines of the message. Those lines decide whether anything below them gets read.

What is the difference between an angel investor and a VC fund?

An angel invests their own money and can decide alone, which usually makes the process shorter. A fund invests money it raised from other people, so it answers to those backers and normally runs a longer diligence process before it commits. Founders often raise from angels first and bring in a fund once there is more to show.

Data: RaiseHunt investor dataset · Snapshot 27 August 2026 · How this data is built · Report a correction or request removal